China all set to use unapproved vaccines for emergency usage


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ China all set to use unapproved vaccines for emergency usage
China is dumping testing procedures, approves vaccines for emergency use

A Chinese health official on Saturday confirmed the country authorized emergency usage of COVID-19 vaccines developed by some select domestic companies on July 22.

“We’ve drawn up a series of plan packages, including medical consent forms, side-effects-monitoring plans, rescuing plans and compensation plans, to make sure the emergency use is well regulated and monitored,” Zheng Zhongwei, head of China’s coronavirus vaccine development task force, told broadcaster CCTV.

An emergency use authorization, which is based on Chinese vaccine management law, allows unapproved vaccine candidates to be used among people who are at high risk of getting infected on a limited period.

By first inoculating the special groups, like front-line medical workers and civil servants, the move is to ensure that a city can keep normal functions when a health crisis strikes, the law states.

Similar authorizations have been legalized in many countries. For example, US Food and Drug Administration allows unapproved medical products to be used in an emergency to diagnose, treat or prevent life-threatening diseases or conditions.

“We are planning to scale up the inoculating group to better prepare for a possible next wave in autumn and winter,” Zheng added.

China’s coronavirus vaccines will be priced close to cost, Zheng said.

“It does not mean that companies cannot make profits,” Zheng said. “Companies should decide on moderate profits, or reasonable profits based on costs.”

A potential coronavirus vaccine being developed by a unit of China National Pharmaceutical Group (Sinopharm) could cost no more than 1,000 yuan (US$144) for two shots, Sinopharm Chairman Liu Jingzhen told state media last week. “(The price) will definitely be lower than what Liu said,” Zheng said.

Meanwhile, a new coronavirus vaccine cultivated within insect cells by West China Hospital of Sichuan University in Chengdu has been approved for human trial, according to local government on Saturday.

Using insect cells to grow proteins for the coronavirus vaccine — a first in China — could speed up large-scale production.

Tags : #ChinaCovidNewsAug24 #ChinaVaccineNewsAug24 #Sinopharm #USFDA #UnapprovedVaccines #Worldcovidnesupdateaug24

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026